+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging

Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging

Magnetic Resonance Imaging 24(8): 1059-1067

A physiological pharmacokinetic (PBPK) model was used to estimate tumor microcirculation in nude mice with a grafted tumor. The kinetics of a rapid clearance blood pool agent, Vistarem, were investigated by dynamic MRI after bolus administration. Signal enhancements were recorded in arterial blood and in tumor tissue. To analyze these data, we developed a whole-body mathematical model of the agent's biodistribution using physiological parameters. The model included six compartments: arterial and venous plasma, tumor (split into capillaries and interstitium), and the rest of the body (also split into capillaries and interstitium). As an application, changes in tumor microcirculation parameters were evaluated in mice receiving either an antiangiogenic treatment (ZD4190) or a placebo. The analysis was performed in a Bayesian framework, and the model was fitted to experimental data using Markov Chain Monte Carlo techniques. Results showed a significant difference in tumor microcirculation between the two groups of mice when the microcirculation parameters are considered together. This whole-body physiological model enables to analyze jointly data in tumor tissue and in arterial blood. This leads to accurate estimates of microcirculation parameters and the evaluation of their uncertainty.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048994595

Download citation: RISBibTeXText

PMID: 16997076

DOI: 10.1016/j.mri.2006.04.002

Related references

Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. International Journal of Cancer 122(9): 1981-1986, 2008

Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clinical Cancer Research 9(1): 355-362, 2003

Evaluation of the reproducibility of a protocol for the pharmacokinetic study of breast tumors by dynamic magnetic resonance imaging. Radiologia 57(1): 44-49, 2017

Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma. Clinical Cancer Research 21(1): 106-112, 2015

Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?. Cancer Journal 21(4): 337-342, 2016

Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. IEEE Transactions on Medical Imaging 25(12): 1627-1636, 2006

Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks. WorldNeurosurgery77(5-6):785.E11, 2012

Monitoring of bevacizumab-induced antiangiogenic treatment effects by "steady state" ultrasmall superparamagnetic iron oxide particles magnetic resonance imaging using robust multiecho ΔR2* relaxometry. Investigative Radiology 46(5): 326-330, 2011

Combined magnetic resonance tractography and functional magnetic resonance imaging in evaluation of brain tumors involving the motor system. Journal of Computer Assisted Tomography 28(4): 551-556, 2004

Dysembryoplastic neuroepithelial tumors: magnetic resonance imaging and magnetic resonance spectroscopy evaluation. Chinese Medical Journal 122(20): 2433-2437, 2009

Evaluation of the microcirculation: advances in cardiac magnetic resonance perfusion imaging. Journal of Nuclear Cardiology 15(5): 698-708, 2008

Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. Journal of Clinical Oncology 29(11): E308-E311, 2011

Role of quantitative magnetic resonance imaging parameters in the evaluation of treatment response in malignant tumors. Chinese Medical Journal 128(8): 1128-1133, 2015

Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittel-Forschung 43(9): 1020-1024, 1993

Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Investigative Radiology 42(12): 791-796, 2007